Shares of Myogen ( MYOG) sank 11% in late trading Monday after the biopharmaceutical company reported lower-than-expected full-year revenue and announced a marketing deal with British pharmaceutical company GlaxoSmithKline ( GSK). For 2005, Myogen posted a loss of $63 million, or $1.68 a share, as compared to a loss of $57.7 million, or $2 a share, a year earlier. Revenue totaled $7 million, compared with $6.6 million in 2004. Analysts polled by Thomson First Call were looking for a smaller loss of $1.72 a share, with revenue of $9.9 million. Myogen announced a distribution deal in which Glaxo received the rights to market ambrisentan, Myogen's pulmonary arterial hypertension drug, outside the U.S. The drug is still in late-stage clinical testing. In turn, Myogen will be responsible for the marketing and distribution of GlaxoSmithKline's Flolan in the United States. Shares of Myogen fell $4.47 to $36.84 in after-hours trading. Texas Instruments ( TXN) slipped after the Dallas-based chipmaker narrowed its first-quarter forecast. The company said it expects to earn between 31 cents and 33 cents a share in its first quarter, compared with its previous guidance of 29 cents to 33 cents. Revenue for the quarter is targeted at $3.22 billion and $3.35 billion, narrower than TI's initial forecast of $3.11 billion to $3.38 billion. The midpoint of the new guidance is $3.28 billion, compared with the previous $3.24 billion midpoint. Analysts' average estimate calls for revenue of $3.27 billion and EPS of 32 cents, according to First Call. Shares fell 97 cents, or 3%, to $31.36 in after-hours trading. Semtech ( SMTC) shares rose modestly after the company's fourth-quarter results narrowly beat analyst estimates. The chipmaker's earnings for the quarter ended Jan. 31 rose to $13.3 million, or 18 cents a share, from $12.1 million, or 16 cents a share, a year earlier. Sales rose to $64.4 million from $58.4 million. Analysts, on average, projected earnings of 17 cents a share and sales of $64.3 million.